Ве молиме користете го овој идентификатор да го цитирате или поврзете овој запис: http://hdl.handle.net/20.500.12188/12940
DC FieldValueLanguage
dc.contributor.authorHalimi Vesaen_US
dc.contributor.authorDaci Armonden_US
dc.contributor.authorRidova Nevenkaen_US
dc.contributor.authorPanovska-Stavridis Irinaen_US
dc.contributor.authorStevanovic Milenaen_US
dc.contributor.authorFilipce Venkoen_US
dc.contributor.authorDimovski Aleksandaren_US
dc.contributor.authorGrozdanova Aleksandraen_US
dc.date.accessioned2021-05-31T12:20:37Z-
dc.date.available2021-05-31T12:20:37Z-
dc.date.issued2020-09-21-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/12940-
dc.language.isoenen_US
dc.publisherJournal of Pharmaceutical Policy and Practiceen_US
dc.subjectCOVID-19, Remdesivir, Clinical practice, Clinical trials, Expanded access, Compassionate use, Early access scheme, Emergency use, Conditional approvalen_US
dc.titleThe use of remdesivir outside of clinical trials during the COVID-19 pandemicen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1186/s40545-020-00258-8-
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Faculty of Pharmacy: Journal Articles
Files in This Item:
File Опис SizeFormat 
s40545-020-00258-8.pdf360.96 kBAdobe PDFView/Open
Прикажи едноставен запис

Page view(s)

65
Last Week
1
Last month
checked on 20.7.2025

Download(s)

14
checked on 20.7.2025

Google ScholarTM

Проверете

Altmetric


Записите во DSpace се заштитени со авторски права, со сите права задржани, освен ако не е поинаку наведено.